COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03001804
Recruitment Status : Recruiting
First Posted : December 23, 2016
Last Update Posted : January 30, 2019
Information provided by (Responsible Party):

Brief Summary:
The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg in> 75 year old patients) and in the registered indication under practice conditions.

Condition or disease
Multiple Myeloma

Detailed Description:
Multiple myeloma is still a persistent and life-threatening blood cancer that is characterised by tumour proliferation and suppression of the immune system. It is a rare but incurable disease. On average, multiple myeloma is diagnosed in people 65-74 years of age, and the majority of newly diagnosed patients may not be eligible for more aggressive treatment options such as high-dose chemotherapy with stem cell transplant. In February 2015 REVLIMID® (lenalidomide) was approved in combination with dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Looking in more detail at the combination of lenalidomide and dexamethasone, the role and especially the most adequate and effective dosage of dexamethasone in long term use with lenalidomide is not clearly defined or well characterised It is therefore of great relevance to gain insights into the clinical practice and the routine of dexamethasone management and dosing in long term use with Revlimid.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 56 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice
Actual Study Start Date : July 31, 2017
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 31, 2021

Lenalidomide (Revlimid®) in combination with dexamethasone
Lenalidomide (Revlimid®) in combination with dexamethasone is indicated for the treatment of adult patients with untreated multiple myeloma, where stem cell transplantation cannot be performed.

Primary Outcome Measures :
  1. Number of patients receiving full dose of dexamethasone after 6 months [ Time Frame: up to 2 years ]
    Number of patients that receive dexamethasone

Secondary Outcome Measures :
  1. Number of patients with Deep Venous Thrombosis (VTE) prophylaxis [ Time Frame: up to 2 years ]
    Number of patients that receive VTE prophylaxis

  2. Over all response rate (ORR) [ Time Frame: up to 2 years ]
    Number of patients that achieve a response

  3. Adverse Events (AEs) [ Time Frame: up to 2 years ]
    Number of patients with an adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients scheduled for therapy of untreated multiple myeloma, where stem cell transplantation cannot be performed

Inclusion Criteria:

  • Signed Informed Consent
  • Age ≥ 18 years
  • Newly diagnosed Multiple Myeloma
  • Not suitable for stem cell transplantation
  • Appropriate methods of contraception according to the Risk Minimization Program (RMP)
  • Adequate thrombosis prophylaxis

Exclusion Criteria:

  • Pregnant and lactating females
  • No other formal exclusion criteria according to most recent European Summary of Product Characteristics (SmPC)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03001804

Layout table for location contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599

Layout table for location information
Landeskrankenhaus Kirchdorf Recruiting
Kirchdorf, Austria, 4560
Klinikum Klagenfurt am Wörthersee Recruiting
Klagenfurt, Austria, 9020
Ordensklinikum Linz GmbH Elisabethinen Recruiting
Linz, Austria, 4020
Krankenhaus der Barmherzigen Schwestern Ried Innere Medizin 1 Recruiting
Ried, Austria, 4910
Landeskrankenhaus Steyr - Innere Medizin Recruiting
Steyr, Austria, 4400
Klinische Abteilung für Hämatologie und Hämostaseologie Recruiting
Vienna, Austria, 1090
St. Josef Krankenhaus Recruiting
Vienna, Austria, 1130
Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie Recruiting
Vienna, Austria, 1160
Salzkammergut-Klinikum Vöcklabruck Abteilung Innere Medizin Recruiting
Vöcklabruck, Austria, 4840
LKH Wiener Neustadt, Innere Medizin Recruiting
Wr. Neustadt, Austria, 2700
Sponsors and Collaborators
Layout table for investigator information
Study Director: Guenter Voraberger Celgene Corporation
Layout table for additonal information
Responsible Party: Celgene Identifier: NCT03001804    
Other Study ID Numbers: CC-5013-MM-037
First Posted: December 23, 2016    Key Record Dates
Last Update Posted: January 30, 2019
Last Verified: January 2019
Keywords provided by Celgene:
Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases